Second-line chemotherapy efficacy is not affected by prior exposure to immunotherapy in extensive-disease small-cell lung cancer: results from the ESME French national real-world cohort

RECOMMENDED

Lung Cancer

Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

ESMO Open

Peters S, Salomonsen RJ, Diaz Perez I, Shcherbakova T, Wang A, Cai L, Sadow S, Liu SV

doi: 10.1016/j.esmoop.2025.106031

Lung Cancer

Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States

Adv Ther

Sankar K, Unni S, Eberl M, Le H, Herrmann T, Gorsh B, Tang M, Coerts F, Ahmed S

doi: 10.1007/s12325-025-03408-z

Lung Cancer

Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study

Oncol Ther

Godbert B, Gobbini E, Khalife Y, Decroisette C, Brellier F, Lena H, Fleuriet A, Zysman M, Egenod T, Girard N

doi: 10.1007/s40487-026-00437-8

Lung Cancer

Real-world comparative effectiveness of sotorasib versus docetaxel monotherapy in second line and beyond for advanced or metastatic non-small cell lung cancer: A national database analysis from England

Lung Cancer

Karim N, Arnold K, Summers Y, Akram T, Trankov N, Vladimirova A, Chopra D, Mesa-Frias M, Waterhouse D, Stollenwerk B

doi: 10.1016/j.lungcan.2026.109469

RECOMMENDED

Lung Cancer

Chemoimmunotherapy Versus Chemotherapy for Extensive-Stage Small Cell Lung Cancer in the Real-World Setting: Retrospective Study of 904 Patients

★ 2 Recommended by Dr. med. Martin Frey, Faculty Member

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Clin Lung Cancer

Dimitriou K, Shi S, Marginenau A, Blasi M, Bozorgmehr F, Klotz LV, Eichhorn F, Schneider MA, Allgäuer M, Shah R, Bischoff H, Weykamp F, Stenzinger A, Thomas M, Christopoulos P

doi: 10.1016/j.cllc.2026.06.004

Lung Cancer

Real-World Effectiveness of Second-Line Therapies in Advanced Non-Small Cell Lung Cancer: Insights From Propensity-Weighted Comparative Analyses of Longitudinal EHR Data

Clin Lung Cancer

Hettinger GCN, Long Q, Parikh RB

doi: 10.1016/j.cllc.2025.09.010

RECOMMENDED

Lung Cancer

Impact of First-Line Maintenance Immunotherapy With or Without Pemetrexed for Non-Squamous Advanced/Metastatic Non-Small Cell Lung Cancer Lacking Targetable Mutations: A Real-World Analysis in England

★ 1 Recommended by Dr. med. Martin Frey, Faculty Member

Clin Lung Cancer

Gomes F, Gilding N, Tan V, Christoforou K, Rule J, Aziez A, Januszewski A, Minchom A

doi: 10.1016/j.cllc.2025.12.007

RECOMMENDED

Lung Cancer

Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the I-STOP study

★ 2 Recommended by Dr. med. Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Eur J Cancer

Gemelli M, Sala L, Morabito A, Sforza V, Cortellini A, La Cava G, Bertolini F, Guaitoli G, Carnio S, Novello S, Leonetti A, Tiseo M, Mazzoni F, Cosso F, Macerelli M, Membrino A, Metro G, Chiari R, Genova C, Berardi R, Tassistro E, Antolini L, Cortinovis DL

doi: 10.1016/j.ejca.2026.116579

RECOMMENDED

Lung Cancer

Real-world comparative effectiveness of atezolizumab versus durvalumab for extensive-stage small-cell lung cancer

★ 1 Recommended by Dr. med. Martin Frey, Faculty Member

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

Lung Cancer

Aiba T, Hara S, Tominaga S, Yamamoto R, Sakashita H, Sakaguchi T, Ando Y, Koshio J, Takigami A, Maemondo M, Sugawara S

doi: 10.1016/j.lungcan.2026.109355

Related content

Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study

Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States

Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study

Real-world comparative effectiveness of sotorasib versus docetaxel monotherapy in second line and beyond for advanced or metastatic non-small cell lung cancer: A national database analysis from England

Chemoimmunotherapy Versus Chemotherapy for Extensive-Stage Small Cell Lung Cancer in the Real-World Setting: Retrospective Study of 904 Patients

Real-World Effectiveness of Second-Line Therapies in Advanced Non-Small Cell Lung Cancer: Insights From Propensity-Weighted Comparative Analyses of Longitudinal EHR Data

Impact of First-Line Maintenance Immunotherapy With or Without Pemetrexed for Non-Squamous Advanced/Metastatic Non-Small Cell Lung Cancer Lacking Targetable Mutations: A Real-World Analysis in England

Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the I-STOP study

Real-world comparative effectiveness of atezolizumab versus durvalumab for extensive-stage small-cell lung cancer